SANA CAS No.42571-07-3 Sport Nutrition & Weight Loss

SANA is a derivative of salicylic acid, with the full name "salicyl nitroenol." Experimental studies have demonstrated that SANA specifically targets adipose tissue and activates thermogenesis through an unconventional mechanism. Thermogenesis is typically mediated by a protein called UCP1, which is present in mitochondria (the organelles responsible for cellular energy production). UCP1 can be activated under certain conditions, such as exposure to cold environments, thereby interfering with the synthesis of cellular fuel ATP (adenosine triphosphate) and leading to the dissipation of energy generated by cellular respiration as heat. In contrast, SANA operates differently: this novel drug enables adipocytes to utilize creatine—a compound derived from three amino acids (arginine, glycine, and methionine)—as an energy source for thermogenesis without involving the UCP1 protein. Consequently, it represents the first class of anti-obesity agents that does not affect the central nervous system, digestive system, or appetite. SANA targets enzymes involved in the so-called "creatinine futile cycle," a thermogenic pathway in which amino acid compounds are repeatedly converted to phosphocreatine and subsequently back to creatine, consuming ATP and releasing energy in the form of heat.